Immunological features of B-linear progenitors on the 15th day of acute lymphoblastic leukemia therapy in children. Comparison of minimal residual disease assessment protocols and own results
Open Access
- 28 March 2020
- journal article
- research article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 58-67
Abstract
Evaluation of minimal residual disease (MRD) on the 15th day of treatment of acute lymphoblastic leukemia from B-linear precursors (B-ALL) in children is of key importance in the prognosis of the disease. When evaluating the MRD, it is necessary to take into account the features of the primary immunophenotype of tumor B-lymphoblasts. To assess the MRD on the 15th day of treatment several immunological approaches have been proposed that have a general concept, but differ in fundamentally important details. The purpose of this work was to analyze the established flow cytometry (FC) protocols of the main research groups (BerlinFrankfurt-Munster Group, St. Jude Hospital, Children’s Oncology Group) and to compare the results evaluated according to those approaches. This study was approved by the Independent Ethical Committee N.N. Blokhin National Medical Cancer Research Center. The study included 131 patients with B-ALL aged 1 to 17 years (median 5.53). Pre-Pre-B immunosubvariant prevailed (92.4%). A morphological (myelogram count) and immunological (MRD assessment) study of the BM was performed in all patients on the 15th day. Comparing the FC protocols of the MRD on the 15th day, it was shown that CD10 was a more reliable criterion for the detection of B-LP in comparison with CD34. The expression of CD45 may serve as an additional criterion for the detection of B-LP. The recalculation of the mononuclear cells is a more stringent criterion for determining the MRD. The scientific novelty is that for the first time on the 15th day, a detailed comparison of flow cytometry data with a cytological picture of the bone marrow was carried out. It was shown for the first time that not all B-LP detected on the basis of CD10+ /CD19+ /CD34+ /CD45low are aberrant according to CD58/CD38.Keywords
This publication has 18 references indexed in Scilit:
- STANDARDIZATION OF FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE MONITORING IN CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. RUSSIA–BELARUS MULTICENTER GROUP EXPERIENCEOncohematology, 2016
- Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone MarrowJournal of Clinical Oncology, 2009
- Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic LeukemiaHematology/Oncology Clinics of North America, 2009
- Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after inductionLeukemia, 2008
- Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemiaBlood, 2002
- Early response to therapy and outcome in childhood acute lymphoblastic leukemiaCancer, 1997
- Potential Long-Term Toxic Effects in Children Treated for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1989
- Neurotoxicity Due to Central Nervous System Therapy for Childhood LeukemiaJournal of Pediatric Hematology/Oncology, 1989
- Long‐term sequelae of cancer treatment on the central nervous system in childhoodMedical and Pediatric Oncology, 1987
- The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1986